老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题

doi:10.35541/cjd.20240383

中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (1): 72-75.doi: 10.35541/cjd.20240383

• 专家笔谈·老年皮肤病 • 上一篇下一篇

老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题

王博^1，2，3 郑捷¹

¹上海交通大学医学院附属瑞金医院皮肤科，上海 200025；²Avera Medical Group Dermatology，Aberdeen，South Dakota，USA；3University of South Dakota，Medical School，South Dakota，USA

收稿日期:2024-07-17 修回日期:2024-12-11 发布日期:2025-01-03
通讯作者: 郑捷 E-mail:jie-zheng2001@126.com

Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs

Wang Bo^1,2,3, Zheng Jie¹

¹Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; ²Avera Medical Group Dermatology, Aberdeen, South Dakota, USA; 3University of South Dakota, Medical School, South Dakota, USA

Received:2024-07-17 Revised:2024-12-11 Published:2025-01-03
Contact: Zheng Jie E-mail:jie-zheng2001@126.com

摘要/Abstract

摘要： 【摘要】银屑病和特应性皮炎是老年人常见的炎症性皮肤病，伴随慢性炎症和免疫失衡，临床治疗面临很多难题。生物制剂和小分子药物的出现显著改善了银屑病和特应性皮炎治疗的效果与安全性，但在老年人中的应用仍面临挑战。老年人常伴有多种共病，诊断需精确和与其他皮肤病鉴别，并应注重组织病理与实验室检测的辅助作用。使用生物制剂和小分子药物治疗老年银屑病和特应性皮炎患者时，应兼顾皮肤症状及全身健康，选择适宜的个体化方案；在治疗过程中须监测药物安全性，尤其须警惕感染、血脂异常及心血管事件等风险。应加强对老年患者的教育以提高对生物制剂及小分子药物的接受度。未来需积累更多临床数据，为老年银屑病和特应性皮炎患者的精准治疗提供依据。

关键词: 银屑病, 皮炎, 特应性, 老年人, 治疗, 生物制剂, 小分子药物, 预后, 药物相关性副作用和不良反应

Abstract: 【Abstract】 Psoriasis and atopic dermatitis are common inflammatory skin diseases in the elderly, characterized by chronic inflammation and immune imbalance, making their management challenging. The emergence of biologics and small-molecule drugs has revolutionized the treatment of psoriasis and atopic dermatitis by markedly improving efficacy and safety compared to conventional therapies. However, their application in elderly patients poses challenges. Due to the presence of comorbidities in elderly patients, accurate diagnosis is critical by differentiating psoriasis and atopic dermatitis from other skin diseases, with an emphasis on the auxiliary role of histopathological examination and laboratory tests. In the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs, comprehensive treatment should address both skin symptoms and systemic health, with careful drug selection tailored to individuals. Safety monitoring, particularly vigilance for risks such as infections, lipid abnormalities, and cardiovascular events, is essential during treatment. Education efforts are needed to improve patient knowledge and acceptance of biologics and small molecule drugs. Future research should focus on accumulating clinical data in elderly populations to provide a basis for precision treatment of elderly patients with psoriasis and atopic dermatitis.

Key words: Psoriasis, Dermatitis, atopic, Aged, Therapy, Biological agents, Small-molecule drugs, Prognosis, Drug-related side effects and adverse reactions

王博郑捷. 老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题[J]. 中华皮肤科杂志, 2025,58(1):72-75. doi:10.35541/cjd.20240383

Wang Bo, Zheng Jie. Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs[J]. Chinese Journal of Dermatology, 2025, 58(1): 72-75.doi:10.35541/cjd.20240383

参考文献 27

［1］	Griffiths C, Armstrong AW, Gudjonsson JE, et al. Psoriasis［J］. Lancet, 2021,397（10281）:1301⁃1315. doi: 10.1016/S0140⁃6736（20）32549⁃6.
［2］	Ständer S. Atopic dermatitis［J］. N Engl J Med, 2021,384（12）:1136⁃1143. doi: 10.1056/NEJMra2023911.
［3］	Shen X, Wang B, Li K, et al. MicroRNA signatures in diagnosis and prognosis of cutaneous T⁃cell lymphoma［J］. J Invest Dermatol, 2018,138（9）:2024⁃2032. doi: 10.1016/j.jid.2018.03. 1500.
［4］	Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents［J］. J Am Acad Dermatol, 2019,80（1）:27⁃40. doi: 10.1016/j.jaad.2018.06.057.
［5］	Megna M, Potestio L, Fabbrocini G, et al. Treating psoriasis in the elderly: biologics and small molecules［J］. Expert Opin Biol Ther, 2022,22（12）:1503⁃1520. doi: 10.1080/14712598.2022. 2089020.
［6］	Bozon A, Nancey S, Serrero M, et al. Risk of infection in elderly patients with inflammatory bowel disease under biologics: a prospective, multicenter, observational, one⁃year follow⁃up comparative study［J］. Clin Res Hepatol Gastroenterol, 2023,47（5）:102107. doi: 10.1016/j.clinre.2023.102107.
［7］	Di Caprio R, Caiazzo G, Cacciapuoti S, et al. Safety concerns with current treatments for psoriasis in the elderly［J］. Expert Opin Drug Saf, 2020,19（4）:523⁃531. doi: 10.1080/14740338. 2020.1728253.
［8］	Ebina K. Drug efficacy and safety of biologics and Janus kinase inhibitors in elderly patients with rheumatoid arthritis［J］. Mod Rheumatol, 2022,32（2）:256⁃262. doi: 10.1093/mr/roab003.
［9］	Migliore A, Bizzi E, Laganà B, et al. The safety of anti⁃TNF agents in the elderly［J］. Int J Immunopathol Pharmacol, 2009,22（2）:415⁃426. doi: 10.1177/039463200902200218.
［10］	Rodríguez⁃Cerdeira C, González⁃Cespón JL, Martínez⁃Herrera E, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin⁃17 inhibitors and their practical management［J］. Ital J Dermatol Venerol, 2021,156（5）:545⁃557. doi: 10.23736/S2784⁃8671.20.06580⁃3.
［11］	Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase Ⅲ, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. doi: 10.1016/j.jaad.2016.11.041.
［12］	Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase Ⅲ, double⁃blind, placebo⁃ and active comparator⁃controlled VOYAGE 2 trial［J］. J Am Acad Dermatol, 2017,76（3）:418⁃431. doi: 10.1016/j.jaad.2016. 11.042.
［13］	Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis （reSURFACE 1 and reSURFACE 2）: results from two randomised controlled, phase 3 trials［J］. Lancet, 2017,390（10091）:276⁃288. doi: 10. 1016/S0140⁃6736（17）31279⁃5.
［14］	Wollenberg A, Blauvelt A, Guttman⁃Yassky E, et al. Tralokinumab for moderate⁃to⁃severe atopic dermatitis: results from two 52⁃week, randomized, double⁃blind, multicentre, placebo⁃controlled phase Ⅲ trials （ECZTRA 1 and ECZTRA 2）［J］. Br J Dermatol, 2021,184（3）:437⁃449. doi: 10.1111/bjd. 19574.
［15］	Boesjes CM, van der Gang LF, Bakker DS, et al. Dupilumab⁃associated lymphoid reactions in patients with atopic dermatitis［J］. JAMA Dermatol, 2023,159（11）:1240⁃1247. doi: 10.1001/jamadermatol.2023.3849.
［16］	Hasan I, Parsons L, Duran S, et al. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study［J］. J Am Acad Dermatol, 2024,91（2）:255⁃258. doi: 10.1016/j.jaad.2024.03.039.
［17］	SCORE2⁃OP working group and ESC Cardiovascular risk collaboration. SCORE2⁃OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions［J］. Eur Heart J, 2021,42（25）:2455⁃2467. doi: 10.1093/eurheartj/ehab312.
［18］	Tashiro T, Sawada Y. Psoriasis and systemic Inflammatory Disorders［J］. Int J Mol Sci, 2022,23（8）:4457. doi: 10.3390/ijms23084457.
［19］	Nguyen T, Wu JJ. Relationship between tumor necrosis factor⁃α inhibitors and cardiovascular disease in psoriasis: a review［J］. Perm J, 2014,18（1）:49⁃54. doi: 10.7812/TPP/13⁃092.
［20］	Akash M, Rehman K, Liaqat A. Tumor necrosis factor⁃alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus［J］. J Cell Biochem, 2018,119（1）:105⁃110. doi: 10.1002/jcb.26174.
［21］	Rosset F, Mastorino L, Dapavo P, et al. Impact of comorbidities in elderly and frail patients and response to biological therapy in psoriasis［J］. Exp Dermatol, 2023,32（7）:1162⁃1164. doi: 10. 1111/exd.14822.
［22］	Noda S, Suárez⁃Fariñas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization［J］. J Allergy Clin Immunol, 2015,136（5）:1254⁃1264. doi: 10.1016/j.jaci.2015. 08.015.
［23］	Kim J, Ahn K. Atopic dermatitis endotypes: knowledge for personalized medicine［J］. Curr Opin Allergy Clin Immunol, 2022,22（3）:153⁃159. doi: 10.1097/ACI.0000000000000820.
［24］	Blauvelt A, Ladizinski B, Prajapati VH, et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate⁃to⁃severe atopic dermatitis: results from an open⁃label extension of the phase 3, randomized, controlled trial （Heads Up）［J］. J Am Acad Dermatol. 2023,89（3）:478⁃485. doi: 10.1016/j.jaad.2023.05.033.
［25］	Lauffer F, Eyerich K. Eczematized psoriasis ⁃ a frequent but often neglected variant of plaque psoriasis［J］. J Dtsch Dermatol Ges, 2023,21（5）:445⁃453. doi: 10.1111/ddg.14991.
［26］	Borren NZ, Ananthakrishnan AN. Safety of biologic therapy in older patients with immune⁃mediated diseases: a systematic review and meta⁃analysis［J］. Clin Gastroenterol Hepatol, 2019,17（9）:1736⁃1743. doi: 10.1016/j.cgh.2018.12.032.
［27］	Chat VS, Ellebrecht CT, Kingston P, et al. Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation［J］. J Am Acad Dermatol, 2024,90（6）:1170⁃1181. doi: 10.1016/j.jaad.2023.12.070.

[1]	李明李妍李邻峰. Janus激酶抑制剂在中重度特应性皮炎中的应用进展[J]. 中华皮肤科杂志, 2025, 58(3): 20220342-e0220342.
[2]	许焯红胡煜顾恒. 间充质干细胞来源的外泌体在皮肤病中的作用[J]. 中华皮肤科杂志, 2025, 58(3): 20220881-e20220881.
[3]	陈嘉琪张禁唐隽. 新型冠状病毒感染与银屑病之间关系的研究进展[J]. 中华皮肤科杂志, 2025, 58(1): 84-88.
[4]	中国康复医学会皮肤病康复专业委员会中国中西医结合学会皮肤性病专业委员会老年皮肤病学组. [开放获取] 老年皮肤瘙痒症诊疗与康复专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(1): 1-8.
[5]	中国康复医学会皮肤病康复专业委员会中国康复医学会光动力治疗与康复专业委员会中华医学会皮肤性病学分会光动力治疗协作组. [开放获取] 氨基酮戊酸光动力疗法治疗非黑色素瘤皮肤癌临床应用专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(1): 9-19.
[6]	廖彩荷王佩茹吴明顺孙晓飞张国龙王秀丽. 联合氨基酮戊酸光动力疗法治疗老年颜面部基底细胞癌的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 34-39.
[7]	吴曹英杨永婷王春申耀元贾卉卉李婷婷赵娟康晓静. 老年黑色素瘤临床病理特征及预后分析[J]. 中华皮肤科杂志, 2025, 58(1): 40-46.
[8]	金兰邱云王唯嘉康晓静丁媛. [开放获取] 生物制剂治疗老年中重度银屑病124例的临床疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 47-52.
[9]	杨子靖陈利红阮叶平文莞廷张嘉艺王海伦潘萌赵肖庆. 度普利尤单抗治疗老年性特应性皮炎的疗效及安全性研究[J]. 中华皮肤科杂志, 2025, 58(1): 65-69.
[10]	艾芳婷孙紫君苗国英姚春霞. 钙敏感受体在老年皮肤病理生理中的作用研究进展[J]. 中华皮肤科杂志, 2025, 58(1): 76-79.
[11]	王迪张瑞珺康玉英. 脂溢性皮炎的发病机制及治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(1): 89-92.
[12]	王瑞霞曲岩磊艾文锦闫琳曲才杰史同新. 非大疱性嗜中性红斑狼疮1例[J]. 中华皮肤科杂志, 2024, 57(9): 832-834.
[13]	向茜张凌燕钟琳高奕邱逦. 鲜红斑痣多模态超声表现及在光动力疗效评估中的应用研究[J]. 中华皮肤科杂志, 2024, 57(9): 801-806.
[14]	张聪聪邵雪宝张莹宋昊王小坡张韡徐秀莲姜祎群曾学思孙建方臧洁陈浩. ALK、TRK及ROS1在Spitz肿瘤中的表达及与临床和组织病理学特征的关系[J]. 中华皮肤科杂志, 2024, 57(9): 807-814.
[15]	乔嘉熙夏萍陈柳青. 司库奇尤单抗治疗前后银屑病局部皮损皮肤镜和反射式共聚焦显微镜特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 825-829.

老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题

Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

Metrics

本文评价

推荐阅读 10